Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 12/20 | 0.33 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434426 | 1.00 | MAPK1 (0.33) | MAPK1JAK2P2RX7CDK4CDK2 | |
| SCHEMBL3770357 | 0.89 | RAPGEF4 (0.30) | — | |
| SCHEMBL3433367 | 0.89 | RAPGEF4 (0.30) | — | |
| SCHEMBL3781782 | 0.86 | MAPK1 (0.33) | MAPK1P2RX7CDK4CDK2 | |
| SCHEMBL3435660 | 0.85 | JAK2 (0.37) | MAPK1JAK2P2RX7CDK4CDK2 | |
| SCHEMBL3783059 | 0.85 | JAK2 (0.37) | MAPK1JAK2P2RX7CDK4CDK2 | |
| SCHEMBL10009558 | 0.82 | MAPK1 (0.34) | MAPK1P2RX7 | |
| SCHEMBL27982242 | 0.82 | MAPK1 (0.34) | MAPK1P2RX7 | |
| SCHEMBL10009796 | 0.82 | MAPK1 (0.34) | MAPK1P2RX7 | |
| SCHEMBL3777850 | 0.81 | GSK3B (0.46) | JAK2CDK4CDK2GSK3BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066343-B | Trisubstituted 1,2, 4-triazoles as nicotinic acetylcholine receptor modulators | JANSSEN PHARMACEUTICA NV | 2013-12-04 | — | — | CN | claimed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | claimed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | MAPK1 1845/4885JAK2 2568/4885P2RX7 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.